Keisuke Otani, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiosurgery | 7 | 2024 | 1331 | 0.670 |
Why?
|
Cholangitis | 3 | 2015 | 108 | 0.630 |
Why?
|
Deoxycytidine | 3 | 2016 | 826 | 0.600 |
Why?
|
Choledocholithiasis | 2 | 2015 | 48 | 0.580 |
Why?
|
Brachytherapy | 6 | 2020 | 1247 | 0.560 |
Why?
|
Radiation-Sensitizing Agents | 4 | 2020 | 358 | 0.540 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 5 | 2015 | 504 | 0.540 |
Why?
|
Prostatic Neoplasms | 10 | 2024 | 11059 | 0.530 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2016 | 640 | 0.510 |
Why?
|
Fractures, Compression | 1 | 2016 | 133 | 0.480 |
Why?
|
Radiotherapy, Intensity-Modulated | 5 | 2021 | 806 | 0.470 |
Why?
|
Radiation Pneumonitis | 1 | 2014 | 104 | 0.450 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 7 | 2021 | 1624 | 0.450 |
Why?
|
Melanocytes | 1 | 2016 | 515 | 0.440 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2012 | 54 | 0.420 |
Why?
|
Drainage | 2 | 2015 | 1142 | 0.400 |
Why?
|
Radiation Injuries | 3 | 2019 | 1180 | 0.390 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2024 | 9239 | 0.370 |
Why?
|
Decompression, Surgical | 1 | 2015 | 594 | 0.360 |
Why?
|
Interleukin-2 | 2 | 2017 | 1904 | 0.360 |
Why?
|
Cell Cycle | 3 | 2019 | 2963 | 0.350 |
Why?
|
Spinal Fractures | 1 | 2016 | 696 | 0.340 |
Why?
|
Bile Ducts, Intrahepatic | 2 | 2006 | 295 | 0.310 |
Why?
|
Gallbladder Diseases | 1 | 2007 | 125 | 0.290 |
Why?
|
Adenoma, Bile Duct | 1 | 2006 | 30 | 0.280 |
Why?
|
Radiotherapy Dosage | 7 | 2021 | 2879 | 0.270 |
Why?
|
Adrenal Cortex Hormones | 2 | 2015 | 1854 | 0.270 |
Why?
|
Salvage Therapy | 3 | 2024 | 1275 | 0.260 |
Why?
|
Pneumonia | 1 | 2017 | 2133 | 0.250 |
Why?
|
Oropharyngeal Neoplasms | 2 | 2020 | 477 | 0.240 |
Why?
|
Anti-Inflammatory Agents | 1 | 2014 | 1789 | 0.240 |
Why?
|
Radiography, Abdominal | 1 | 2007 | 537 | 0.240 |
Why?
|
Epithelial Cells | 1 | 2016 | 3690 | 0.240 |
Why?
|
Radium | 1 | 2024 | 65 | 0.230 |
Why?
|
Abdomen | 2 | 2017 | 1117 | 0.220 |
Why?
|
Stents | 1 | 2015 | 3280 | 0.220 |
Why?
|
Gastrointestinal Diseases | 2 | 2023 | 1171 | 0.220 |
Why?
|
Intracranial Aneurysm | 3 | 2017 | 1197 | 0.210 |
Why?
|
Osteosarcoma | 2 | 2017 | 881 | 0.210 |
Why?
|
Liver Neoplasms | 2 | 2018 | 4251 | 0.200 |
Why?
|
Models, Anatomic | 2 | 2017 | 690 | 0.200 |
Why?
|
Radiotherapy | 2 | 2019 | 1533 | 0.190 |
Why?
|
Pancreatic Neoplasms | 2 | 2016 | 5264 | 0.190 |
Why?
|
Cysts | 1 | 2006 | 678 | 0.190 |
Why?
|
Prostate-Specific Antigen | 4 | 2024 | 2471 | 0.190 |
Why?
|
Bile Duct Neoplasms | 1 | 2006 | 567 | 0.180 |
Why?
|
Male Urogenital Diseases | 1 | 2019 | 48 | 0.170 |
Why?
|
Particle Accelerators | 1 | 2019 | 173 | 0.170 |
Why?
|
Uterine Cervical Neoplasms | 3 | 2020 | 2018 | 0.170 |
Why?
|
Human papillomavirus 16 | 1 | 2020 | 261 | 0.170 |
Why?
|
Organs at Risk | 1 | 2021 | 346 | 0.160 |
Why?
|
Carcinosarcoma | 1 | 2019 | 108 | 0.160 |
Why?
|
Prostate | 2 | 2024 | 1763 | 0.160 |
Why?
|
Papillomavirus Infections | 2 | 2020 | 1587 | 0.150 |
Why?
|
Amines | 1 | 2019 | 276 | 0.150 |
Why?
|
Liver Diseases | 1 | 2006 | 1253 | 0.150 |
Why?
|
Melanoma | 1 | 2016 | 5508 | 0.150 |
Why?
|
Radiation Tolerance | 2 | 2020 | 486 | 0.150 |
Why?
|
Aged, 80 and over | 16 | 2020 | 57744 | 0.150 |
Why?
|
Japan | 3 | 2018 | 1360 | 0.150 |
Why?
|
Gastrointestinal Tract | 2 | 2020 | 814 | 0.140 |
Why?
|
Glutamates | 1 | 2018 | 397 | 0.140 |
Why?
|
Radiometry | 2 | 2019 | 800 | 0.140 |
Why?
|
Pancreatitis | 3 | 2015 | 1092 | 0.130 |
Why?
|
Vaginal Neoplasms | 1 | 2016 | 105 | 0.130 |
Why?
|
Neurosurgical Procedures | 3 | 2017 | 2002 | 0.130 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2019 | 446 | 0.130 |
Why?
|
Aged | 25 | 2023 | 163178 | 0.130 |
Why?
|
Prostatectomy | 1 | 2024 | 1879 | 0.130 |
Why?
|
Male | 31 | 2024 | 349776 | 0.130 |
Why?
|
Decision Trees | 1 | 2017 | 506 | 0.130 |
Why?
|
Cell Physiological Phenomena | 1 | 2016 | 154 | 0.120 |
Why?
|
Phantoms, Imaging | 2 | 2019 | 2479 | 0.120 |
Why?
|
Humans | 45 | 2024 | 743811 | 0.120 |
Why?
|
Middle Aged | 22 | 2020 | 213241 | 0.120 |
Why?
|
Benzimidazoles | 1 | 2019 | 850 | 0.120 |
Why?
|
Fractures, Spontaneous | 1 | 2016 | 230 | 0.120 |
Why?
|
Lung Neoplasms | 3 | 2020 | 13112 | 0.120 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2018 | 690 | 0.120 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2020 | 4033 | 0.110 |
Why?
|
Surgical Instruments | 1 | 2016 | 395 | 0.110 |
Why?
|
Hospitals, University | 1 | 2015 | 570 | 0.110 |
Why?
|
Androgens | 1 | 2020 | 1247 | 0.110 |
Why?
|
Respiration | 1 | 2019 | 1653 | 0.110 |
Why?
|
Retrospective Studies | 11 | 2024 | 77410 | 0.110 |
Why?
|
Movement | 1 | 2019 | 1471 | 0.100 |
Why?
|
Injections, Intramuscular | 1 | 2012 | 553 | 0.100 |
Why?
|
Treatment Outcome | 11 | 2023 | 63042 | 0.100 |
Why?
|
Doxorubicin | 1 | 2018 | 2234 | 0.100 |
Why?
|
Cell Line, Tumor | 5 | 2020 | 16674 | 0.100 |
Why?
|
Breast Neoplasms | 2 | 2019 | 20827 | 0.100 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2023 | 2248 | 0.100 |
Why?
|
Epidemiologic Methods | 1 | 2016 | 1364 | 0.090 |
Why?
|
Survival Rate | 6 | 2020 | 12786 | 0.090 |
Why?
|
Antioxidants | 1 | 2018 | 1658 | 0.090 |
Why?
|
Preoperative Care | 2 | 2016 | 2251 | 0.090 |
Why?
|
Sphincterotomy, Endoscopic | 1 | 2009 | 41 | 0.090 |
Why?
|
Adenocarcinoma | 2 | 2018 | 6363 | 0.080 |
Why?
|
Urogenital System | 2 | 2019 | 86 | 0.080 |
Why?
|
Mastectomy, Segmental | 1 | 2014 | 956 | 0.080 |
Why?
|
Quality Assurance, Health Care | 1 | 2019 | 2211 | 0.080 |
Why?
|
Esophageal Neoplasms | 1 | 2019 | 1585 | 0.080 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2014 | 1770 | 0.080 |
Why?
|
Algorithms | 2 | 2019 | 13869 | 0.080 |
Why?
|
Stomach Neoplasms | 1 | 2017 | 1332 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 6 | 2020 | 20121 | 0.080 |
Why?
|
Vascular Surgical Procedures | 1 | 2017 | 1476 | 0.080 |
Why?
|
Colorectal Neoplasms | 2 | 2020 | 6773 | 0.080 |
Why?
|
Gabexate | 1 | 2007 | 12 | 0.080 |
Why?
|
Torsion Abnormality | 1 | 2007 | 93 | 0.070 |
Why?
|
Neurosurgery | 1 | 2013 | 643 | 0.070 |
Why?
|
Endometrial Neoplasms | 1 | 2016 | 1350 | 0.070 |
Why?
|
Acute Disease | 2 | 2015 | 7150 | 0.070 |
Why?
|
Kidney Diseases | 1 | 2018 | 2146 | 0.070 |
Why?
|
Female | 20 | 2020 | 380020 | 0.070 |
Why?
|
Mice, Inbred C3H | 2 | 2017 | 964 | 0.070 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2736 | 0.070 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2007 | 230 | 0.070 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2018 | 2217 | 0.070 |
Why?
|
Ultrasonography, Doppler | 1 | 2007 | 458 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 2017 | 2529 | 0.060 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2015 | 1861 | 0.060 |
Why?
|
Radiation Dosage | 3 | 2019 | 1928 | 0.060 |
Why?
|
Education, Medical, Graduate | 1 | 2017 | 2291 | 0.060 |
Why?
|
Feasibility Studies | 3 | 2019 | 5078 | 0.060 |
Why?
|
Postoperative Complications | 3 | 2016 | 15281 | 0.060 |
Why?
|
Glioma | 1 | 2019 | 3401 | 0.060 |
Why?
|
Antibodies, Monoclonal | 2 | 2017 | 9272 | 0.060 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2016 | 876 | 0.060 |
Why?
|
Palliative Care | 1 | 2019 | 3490 | 0.060 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2023 | 105 | 0.060 |
Why?
|
Imaging, Three-Dimensional | 3 | 2019 | 4033 | 0.060 |
Why?
|
Models, Biological | 2 | 2019 | 9582 | 0.060 |
Why?
|
Antineoplastic Agents | 2 | 2017 | 13691 | 0.060 |
Why?
|
Autoimmune Diseases | 1 | 2015 | 2134 | 0.060 |
Why?
|
Androgen Antagonists | 2 | 2023 | 1376 | 0.050 |
Why?
|
Recombinant Proteins | 1 | 2012 | 6620 | 0.050 |
Why?
|
Colitis, Ulcerative | 1 | 2015 | 1911 | 0.050 |
Why?
|
Tumor Burden | 2 | 2019 | 1917 | 0.050 |
Why?
|
Recurrence | 1 | 2014 | 8337 | 0.050 |
Why?
|
Crohn Disease | 1 | 2015 | 2304 | 0.050 |
Why?
|
Immunotherapy | 1 | 2017 | 4437 | 0.050 |
Why?
|
Adult | 10 | 2020 | 213889 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 35409 | 0.050 |
Why?
|
Animals | 7 | 2019 | 168660 | 0.050 |
Why?
|
Clinical Competence | 1 | 2017 | 4687 | 0.050 |
Why?
|
Abdominal Pain | 1 | 2007 | 1064 | 0.050 |
Why?
|
Cerebral Angiography | 2 | 2017 | 1285 | 0.050 |
Why?
|
Ouabain | 1 | 2020 | 264 | 0.040 |
Why?
|
Mutation | 1 | 2024 | 29777 | 0.040 |
Why?
|
Biopsy | 2 | 2015 | 6750 | 0.040 |
Why?
|
Pancreas | 1 | 2006 | 1686 | 0.040 |
Why?
|
Glycoproteins | 1 | 2007 | 2266 | 0.040 |
Why?
|
Cystectomy | 1 | 2023 | 686 | 0.040 |
Why?
|
Combined Modality Therapy | 3 | 2017 | 8637 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2019 | 8856 | 0.040 |
Why?
|
DNA Damage | 2 | 2019 | 2429 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6539 | 0.040 |
Why?
|
Gamma Rays | 1 | 2019 | 320 | 0.040 |
Why?
|
Receptors, Androgen | 1 | 2024 | 1055 | 0.040 |
Why?
|
Cisplatin | 1 | 2023 | 1662 | 0.040 |
Why?
|
Lipid Peroxidation | 1 | 2018 | 270 | 0.040 |
Why?
|
Lymphocyte Subsets | 1 | 2017 | 315 | 0.040 |
Why?
|
Mice | 3 | 2019 | 81154 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2023 | 3617 | 0.030 |
Why?
|
Angiography, Digital Subtraction | 1 | 2017 | 341 | 0.030 |
Why?
|
Hepatitis C | 1 | 2006 | 1591 | 0.030 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 902 | 0.030 |
Why?
|
Glutathione | 1 | 2018 | 590 | 0.030 |
Why?
|
Superoxide Dismutase | 1 | 2018 | 595 | 0.030 |
Why?
|
Lasers | 1 | 2019 | 949 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10940 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2617 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2020 | 944 | 0.030 |
Why?
|
DNA, Viral | 1 | 2020 | 2226 | 0.030 |
Why?
|
HCT116 Cells | 1 | 2015 | 409 | 0.030 |
Why?
|
Risk Factors | 3 | 2018 | 72252 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39001 | 0.030 |
Why?
|
G1 Phase | 1 | 2015 | 415 | 0.030 |
Why?
|
Prognosis | 3 | 2019 | 29052 | 0.030 |
Why?
|
Gastrectomy | 1 | 2017 | 663 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2019 | 1119 | 0.030 |
Why?
|
Ultrasonography | 1 | 2006 | 5986 | 0.030 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2019 | 868 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2007 | 12954 | 0.030 |
Why?
|
Neuronavigation | 1 | 2013 | 167 | 0.030 |
Why?
|
Middle Cerebral Artery | 1 | 2013 | 264 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 1038 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2015 | 765 | 0.030 |
Why?
|
Propensity Score | 1 | 2018 | 1781 | 0.030 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2020 | 1523 | 0.020 |
Why?
|
Spleen | 1 | 2017 | 2359 | 0.020 |
Why?
|
Computer Graphics | 1 | 2013 | 360 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12243 | 0.020 |
Why?
|
Apoptosis | 2 | 2019 | 9718 | 0.020 |
Why?
|
DNA Repair | 1 | 2019 | 2045 | 0.020 |
Why?
|
Educational Measurement | 1 | 2017 | 1210 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2017 | 2924 | 0.020 |
Why?
|
Lymphocytes | 1 | 2017 | 2615 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2020 | 2727 | 0.020 |
Why?
|
Prospective Studies | 3 | 2024 | 53250 | 0.020 |
Why?
|
Phosphorylation | 1 | 2019 | 8436 | 0.020 |
Why?
|
Brain Mapping | 1 | 2023 | 6622 | 0.020 |
Why?
|
Regression Analysis | 1 | 2018 | 6457 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5714 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 4848 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2018 | 8300 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2018 | 3082 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3089 | 0.020 |
Why?
|
Biological Products | 1 | 2015 | 859 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6895 | 0.020 |
Why?
|
Cell Survival | 1 | 2016 | 5881 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2015 | 1580 | 0.020 |
Why?
|
Software | 1 | 2019 | 4440 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2017 | 4477 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2017 | 2988 | 0.010 |
Why?
|
Logistic Models | 1 | 2019 | 13404 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2015 | 4561 | 0.010 |
Why?
|
Emergencies | 1 | 2009 | 1170 | 0.010 |
Why?
|
Computer Simulation | 1 | 2016 | 6188 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2019 | 8939 | 0.010 |
Why?
|
Kidney | 1 | 2018 | 7185 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2009 | 1131 | 0.010 |
Why?
|
Young Adult | 2 | 2019 | 56392 | 0.010 |
Why?
|
Databases, Factual | 1 | 2015 | 7729 | 0.010 |
Why?
|
Adolescent | 2 | 2019 | 85729 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2015 | 8430 | 0.010 |
Why?
|
Risk Assessment | 1 | 2020 | 23327 | 0.010 |
Why?
|
Time Factors | 1 | 2020 | 40038 | 0.010 |
Why?
|
Prevalence | 1 | 2015 | 15211 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 11524 | 0.010 |
Why?
|
Incidence | 1 | 2015 | 20948 | 0.010 |
Why?
|
Internship and Residency | 1 | 2017 | 5787 | 0.010 |
Why?
|
Length of Stay | 1 | 2009 | 6311 | 0.010 |
Why?
|
Age Factors | 1 | 2009 | 18355 | 0.010 |
Why?
|
Child | 1 | 2019 | 77637 | 0.010 |
Why?
|
Hospitalization | 1 | 2009 | 10259 | 0.010 |
Why?
|